3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Glioblastoma
11
Brain Neoplasms
11
Gliosarcoma
9
Neuroblastoma
5
Astrocytoma
5
Oligodendroglioma
4
Glioma
4
Carcinoma, Renal Cell
4
Sarcoma, Ewing
3
Sarcoma
3
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Recurrence
3
Neoplasms, Germ Cell and Embryonal
3
Central Nervous System Neoplasms
3
Breast Neoplasms
3
Wilms Tumor
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neurofibromatosis 2
2
Neurofibromatosis 1
2
Neoplasms
2
Melanoma
2
Medulloblastoma
2
Ependymoma
2
Carcinoma, Hepatocellular
2
Vestibulocochlear Nerve Diseases
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
Filgrastim
8
Granulocyte Colony-Stimulating Factor
7
Thiotepa
6
Etoposide
5
Carboplatin
5
Peripheral Blood Stem Cell Transplantation
4
Cyclophosphamide
4
Busulfan
4
Melphalan
3
Ifosfamide
3
Topotecan
2
Mesna
2
sargramostim
1
racotumomab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
etoposide phosphate
1
cixutumumab
1
becatecarin
1
alvocidib
1
Vincristine
1
Ursodeoxycholic Acid
1
Thrombopoietin
1
Thalidomide
1
Temozolomide
1
Stem Cell Transplantation
1
Sirolimus
1
Simvastatin
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Retinoblastoma
×
Sirolimus
×
CNS
×
Clear all
NCT01331135
2020-05-29
Aflac ST0901
Emory University
Phase 1
Completed
18 enrolled